SCHEMBL23901685

SCHEMBL23901685

Cc1cc(-c2cccnc2)nc2c(C(=O)NC(c3cccs3)C(F)(F)F)ncn12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ABL1 P00519 4/20 0.35
PDGFRB P09619 1/20 0.35
SRC P12931 1/20 0.35
PDGFRA P16234 1/20 0.35
MAPT P10636 3/20 0.34
KCNT1 Q5JUK3 1/20 0.34
BCR P11274 3/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
MEN1 O00255 1/20 0.34
ATR Q13535 2/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479245 0.86 TACR3 (0.37) AHRALDH1A1KDM4EMAPK1LMNA
SCHEMBL19438221 0.85 CNR2 (0.42) AHRALDH1A1KDM4EMAPK1LMNA
SCHEMBL23901580 0.83 PKM (0.33) ALDH1A1KDM4EHPGDMAPTPOLB
SCHEMBL19437868 0.81 AHR (0.37) AHRALDH1A1KDM4EMAPK1LMNA
SCHEMBL23901573 0.80 DYRK1A (0.37) AHRALDH1A1KDM4EMAPK1LMNA
SCHEMBL23901681 0.79 PIM1 (0.33) LMNA
SCHEMBL19449609 0.78 DYRK1A (0.47) ALDH1A1KDM4EMAPK1LMNAHPGD
SCHEMBL21479248 0.77 CTSA (0.37) AHRALDH1A1KDM4EMAPK1LMNA
SCHEMBL19438315 0.76 RIPK1 (0.43) ALDH1A1KDM4EABL1PDGFRBPDGFRA
SCHEMBL19438317 0.76 RIPK1 (0.43) ALDH1A1KDM4EABL1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 AHR 1072/4885ALDH1A1 1121/4885KDM4E 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.